Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIOMARIN PHARMACEUTICAL INC.

(BMRN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BioMarin Pharmaceutical : Baird Starts BioMarin Pharmaceutical at Outperform with $101 Price Target

06/04/2021 | 10:52am EDT


ę MT Newswires 2021
All news about BIOMARIN PHARMACEUTICAL INC.
08/04INSIDER TRENDS : 90-Days of Insider Buying at BioMarin Pharmaceuticals Eased Bac..
MT
07/30BIOMARIN PHARMACEUTICAL : Management's Discussion and Analysis of Financial Cond..
AQ
07/29BIOMARIN PHARMACEUTICAL : Piper Sandler Adjusts Price Target on BioMarin Pharmac..
MT
07/29BIOMARIN PHARMACEUTICAL : Oppenheimer Adjusts BioMarin Pharmaceutical PT to $81 ..
MT
07/29BIOMARIN PHARMACEUTICAL : RBC Lifts Price Target on BioMarin Pharmaceutical to $..
MT
07/28BIOMARIN : Q2 Earnings Snapshot
AQ
07/28BIOMARIN PHARMACEUTICAL : Debra Charlesworth (Form 8-K)
PU
07/28BIOMARIN PHARMACEUTICAL : Pharma Swings to Q2 Profit on Rising Revenue, Raises F..
MT
07/28BIOMARIN PHARMACEUTICAL INC : Results of Operations and Financial Condition, Fin..
AQ
07/28Biomarin Pharmaceutical Inc. Raises Earnings Guidance for the Full Year of 20..
CI
More news
Financials (USD)
Sales 2021 1 850 M - -
Net income 2021 -87,5 M - -
Net cash 2021 234 M - -
P/E ratio 2021 -165x
Yield 2021 -
Capitalization 14 289 M 14 289 M -
EV / Sales 2021 7,60x
EV / Sales 2022 6,34x
Nbr of Employees 3 059
Free-Float 99,4%
Chart BIOMARIN PHARMACEUTICAL INC.
Duration : Period :
BioMarin Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMARIN PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 77,93 $
Average target price 108,43 $
Spread / Average Target 39,1%
EPS Revisions
Managers and Directors
Jean-Jacques BienaimÚ Chairman & Chief Executive Officer
Brian R. Mueller Chief Financial Officer & Executive Vice President
Henry J. Fuchs President-Worldwide Research & Development
Eduardo E. Von Pervieux Chief Information Officer
Geoffrey M. Nichol Chief Medical Officer & Senior Vice President
Sector and Competitors